Just been digging into FMC stock and honestly, it's looking like a case study in how fast things can unravel. The agricultural chemicals company got absolutely hammered after reporting Q3 earnings back in October -- we're talking stock price cut nearly in half. They reported a 49% drop in sales while exiting India, posted a massive $4.52 per share loss, and fired their president. Pretty rough.

Fast forward to Q4 earnings earlier this month and... yeah, they missed again. Revenue guidance came in below expectations and management warned about further declines ahead. At this point you'd think FMC stock would be in free fall, like a falling knife endlessly dropping and too dangerous to catch. But here's what's interesting: it actually isn't.

Since that Q3 disaster, the stock has basically been treading water between $13 and $17. It's trading around $14.50 now, which is basically where it was three months ago when everything hit the fan. So despite the terrible earnings, there's actually been some stabilization happening.

Now, don't get me wrong -- FMC is still dealing with serious issues. Full-year 2025 revenue dropped 18%, down 8% even if you exclude the India exit. The company lost $17.88 per diluted share on a stock worth $14.48. That's a painful position to be in.

But here's the thing: the core business still matters. Farmers need agricultural chemicals. Food production isn't going anywhere, and neither is the demand for what FMC actually produces. That demand is still real.

What's changed recently is that management is finally taking action. They announced they'd explore strategic options to maximize shareholder value, which basically means they're open to selling the company. If that happens, you might see a premium. But if they stay independent, they're working on a turnaround plan.

The plan involves raising about $1 billion through asset sales and licensing deals to pay down their $3.5 billion net debt. They're also commercializing four new herbicides and fungicides they've developed -- Isoflex, fluindapyr, Dodhylex, and rimisoxafen -- which could eventually help grow revenue.

Here's the catch though: any turnaround is going to take time. Management is forecasting another 5% revenue decline in 2026 down to $3.7 billion, with adjusted EBITDA dropping 41%. They're expecting break-even free cash flow this year.

They think things improve by 2027 when free cash flow could hit around $190 million. That sounds okay on paper, but the company's valuation is still expensive at around 30 times FCF when you factor in the debt load.

So is FMC a buy? Honestly, unless you're really confident they'll get acquired at a premium or you want to gamble on a successful turnaround, I'd probably pass. The risk-reward just doesn't feel compelling right now. There are better opportunities out there for your money.